Wolverine Trading, LLC Apellis Pharmaceuticals, Inc. Transaction History

Wolverine Trading, LLC

$133 Billion
Q3 2025

A detailed history of Wolverine Trading, LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Wolverine Trading, LLC holds 14,480 shares of APLS stock, worth $294,378. This represents 0.0% of its overall portfolio holdings.

Number of Shares

14,480

Previous 16,198 10.61%

Holding current value

$294,378

Previous $280,000 16.79%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$17.42 - $28.65 $29,927 - $49,220	-1,718 Reduced 10.61%	14,480 $327,000
Q2 2025 Aug 18, 2025	BUY	$16.36 - $23.0 $45,317 - $63,710	2,770 Added 20.63%	16,198 $280,000
Q1 2025 May 15, 2025	BUY	$21.87 - $34.63 $62,373 - $98,764	2,852 Added 26.97%	13,428 $293,000
Q4 2024 Feb 14, 2025	SELL	$26.18 - $35.42 $68,643 - $92,871	-2,622 Reduced 19.87%	10,576 $337,000
Q3 2024 Nov 14, 2024	BUY	$28.84 - $41.15 $114,840 - $163,859	3,982 Added 43.21%	13,198 $380,000

Q2 2024 Aug 14, 2024	SELL	$38.07 - $59.71 $117,331 - $184,026	-3,082 Reduced 25.06%	9,216 $353,000
Q1 2024 May 15, 2024	BUY	$55.39 - $72.47 $309,020 - $404,310	5,579 Added 83.03%	12,298 $722,000
Q4 2023 Feb 14, 2024	SELL	$37.14 - $64.82 $581,426 - $1.01 Million	-15,655 Reduced 69.97%	6,719 $402,000
Q3 2023 Nov 15, 2023	BUY	$23.65 - $89.22 $529,145 - $2 Million	22,374 New	22,374 $851,000
Q1 2023 May 15, 2023	BUY	$46.59 - $66.96 $277,955 - $399,483	5,966 New	5,966 $394,000
Q3 2021 Nov 12, 2021	BUY	$31.4 - $69.84 $1.04 Million - $2.31 Million	33,143 New	33,143 $1.13 Million

Others Institutions Holding APLS

# of Institutions

330

Shares Held

124M

Call Options Held

4.15M

Put Options Held

769K

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.23B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.

Account

Wolverine Trading, LLC Apellis Pharmaceuticals, Inc. Transaction History